Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
July 2015
-
Media Release
Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3… -
Media Release
Novartis: solide performance au deuxième trimestre grâce à la force de l'innovation et aux progrès des nouveaux lancements
Croissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le… -
Media Release
Novartis erzielt im zweiten Quartal eine solide Performance mit starken Innovationen und Fortschritten bei Neueinführungen
Die fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7… -
Media Release
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
WHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for… -
Story From Our Labs
How I built a mini-gut with next to no biology training
-
Story Discovery
Rewriting the playbook for clinical testing in a rare disease
A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.
-
Media Release
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization
First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment… -
Story Patient Perspectives
Surviving with heart failure
Heart failure affects 26 million people worldwide. Half die within five years of diagnosis. There's been a lack of progress in finding more effective medications. Advances in understanding mean new options for patients and caregivers.
-
Media Release
Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…
June 2015
-
Media Release
Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
New features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps… -
Media Release
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic… -
Media Release
Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients
In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…